登录

Sciobio Got Stragic Investment from Green Pine Capital

作者: Mailman 2020-03-02 17:59
赛恩贝
http://www.sciobio.com/
企业数据由 动脉橙 提供支持
创新器械及创新药物研发商 | 战略融资 | 运营中
中国-四川
2020-02-29
松禾资本
查看

According to lieyunwang.com, Green Pine Capital announced that Chengdu Saienbei Biotechnology Co., Ltd. ("Sciobio"), whose high-end products are playing an important role in the prevention and control of the coronavirus epidemic, has obtained its investment recently.


Sciobio was established in March 2015 and the legal representative is Zhang Yu. Luo Zhongli, one of the team members, was once a doctor under the guidance of academician Zhang Shuguang, a world-renowned biological scientist and the postdoctoral fellow of academician Bengt Norden, former chairman of the Nobel Prize selection committee for chemistry. The company has deep academic and technology roots.


The spray product developed by Sciobio has got the certificate last year, which is mainly used for wounds that are slow and difficult to heal, such as resistant microorganisms (including virus, mycoplasma, chlamydia, bacteria) infection in advanced diabetes. In addition to replacing alcohol and other traditional disinfectant liquids, the spray can also be sprayed on the mouth, nasal cavity, eyes and other mucosal parts, which can effectively prevent the spread and invasion of the new coronavirus.


The product can be used not only for the protection and prevention of first-line medical staff but also for the protection and prevention of suspected, confirmed patients or people in active isolation. It is more suitable for the general public. The interventional treatment combining with this product of patients with new coronavirus is still in the clinical application stage.


At present, more than 100 hospitals across the country, involving tens of thousands of first-line medical staff and people are using the spray for protection, and no case of infection after use has been reported.


>>>>
About Green Pine Capital


Founded in 2007, Green Pine Capital is one of the most time-honored venture capital institutions in China, with rich experience in biomedicine, new energy and materials, advanced manufacturing, artificial intelligence, and other fields. The company not only provides funds for the invested enterprises, but also provides high-quality post-investment services and integrated resources. Green Pine Capital manages funds of ten billion yuan and has invested more than 7 billion yuan.


相关赛道 生物制药
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

ZhenGe Biotech banks $51M in Series A Round, Focusing on Macromolecular Drugs, CDMO and Medium

China Immunotech Snags ¥45M in Series A Funding Round

Stemirna Therapeutics Snares ¥10 million in Series A+ Round from Junshi Biosciences, Providing mRNA Vaccines

Diagnostics Firm GensKey Raises ¥50M in Series B+ Round of Financing

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

广东互联网医院开通慢病续方医保结算,微信打通医保支付全场景

2020-03-02
下一篇

DR.BEI Closes on ¥10M Series A Funding Round

2020-03-02